31 stories found
The US Food and Drug Administration has granted approval to Takeda Pharmaceutical’s drug Mimrylo for the treatment of polycythemia vera. The medication targets patients with this rare myeloproliferative neoplasm, offering a new therapeutic option.
Takeda Pharmaceutical has released its first-quarter financial results.
Takeda Pharmaceutical announced plans to invest $30 million in Indonesia's new national plasma donation network, aiming to strengthen the country's healthcare infrastructure.
Julie Kim, Takeda's new CEO, stated at her first news conference that the company aims for a return to growth within three years, targeting a return on equity of at least 5%.
Takeda's application for an expanded label for its drug Entyvio, to include use in children, is currently under review by the FDA.
A U.S. jury has found Takeda Pharmaceuticals guilty of an antitrust 'pay-for-delay' scheme, determining the company unlawfully delayed the market entry of a generic version of its constipation drug, Amitiza. This verdict comes after allegations of anti-competitive practices.
Several companies, including LogicMark, NKT A/S, and Intuitive Machines, have released or previewed their quarterly financial results. These reports detail earnings per share, revenue, and provide transcripts or summaries of earnings calls for Q1 2026, Q1 2025, and Q2 2025.
Takeda Pharmaceutical Company has announced that its drug Rusfertide has been granted Priority Review by the FDA for the treatment of Polycythemia Vera (PV).
Liberal Democratic Party member Ryota Takeda told members of the group that exchanges between Japanese and South Korean lawmakers have helped sustain bilateral ties.
Takeda is reportedly planning to lay off 400 employees in the United States as part of its operational adjustments.
This article explores whether Keros Therapeutics (KROS)'s $20 million milestone from Takeda Pharmaceutical Company Limited (TAK) could unlock a billion-dollar opportunity for the company.
Takeda and the Indonesian government announced a groundbreaking partnership on July 13, 2026, focused on strengthening the plasma ecosystem and broadening patient access to vital pharmaceutical products, with implications for Greece.
Takeda has made a new investment in AI-driven drug discovery by partnering with Insilico Medicine, aiming to leverage artificial intelligence for pharmaceutical innovation.
Takeda has officially appointed Julie Kim as its new President and CEO, finalizing an 18-month transition period.
Takeda Pharmaceutical Company Limited is reportedly facing significant legal risk following a U.S. jury's ruling concerning a generic drug delay.
The Japanese pharmaceutical company Takeda is eliminating 280 positions at its Zurich headquarters in Switzerland, with a social plan in place to support affected employees.
Investors are paying close attention to Takeda's next wave of drugs, anticipating their potential impact on the pharmaceutical market. The company's pipeline is a key focus for market watchers.
Two foil surfers, Tavis Boise and Ron Takeda, recounted the moment a shark pursued them while they were surfing in Santa Barbara, California.
Pharmaceutical company Takeda has announced that its new pill for treating psoriasis has achieved positive results in its late-stage clinical studies.
Wall Street experienced market fluctuations following the Federal Reserve's interest rate decision and new inflation figures. Major tech companies like Microsoft, Apple, and Meta reported earnings, with investor focus on AI spending and its impact on future growth.
India has approved its first dengue vaccine, Qdenga by Takeda, for individuals aged 4 to 60, following clearance from the DCGI. This marks a significant step in the country's efforts to combat dengue fever.
Takeda Pharmaceutical Company Limited (TAK) stock is being evaluated for growth potential following the release of strong data from its LATITUDE Atlas Study.
A late-stage clinical study has shown that Takeda's psoriasis drug demonstrated superior performance compared to Bristol-Myers' Sotyktu, indicating a potential new treatment option for the condition.
Pharmaceutical company Takeda is facing an $885 million financial impact following a landmark "pay-for-delay" lawsuit verdict.
Takeda Pharmaceuticals is set to eliminate 4,500 jobs globally as part of a major cost-cutting initiative aimed at streamlining operations and improving financial efficiency.
Pharmaceutical company Takeda is implementing its second cost-saving program in two years, resulting in the elimination of 280 jobs at its European headquarters in Opfikon, Switzerland, following 120 layoffs two years prior.
Bernstein has upgraded Takeda Pharmaceutical (TAK) to an 'Outperform' rating, suggesting a positive forecast for the company's stock performance.
Takeda Pharmaceutical Company is undertaking a business revamp with the goal of achieving 200 billion yen in savings by fiscal year 2028.
Jack Dorsey Rolf Vennenbernd/picture alliance via Getty Images Naoko Takeda wrote on LinkedIn that Block offered her a pay bump and retention bonus after its recent layoffs. Takeda said she quit instead. "That's not an honor. It feels shameful and dehumanizing," she wrote. Business Insider viewed messages in which two employees said their retention bonuses were $60,000 and $80,000. Survived the Block layoffs? You might be getting a hefty retention package, including a bonus. Naoko Takeda wa...